(Reuters) – Biogen Inc’s second-quarter profit more than doubled on Wednesday, driven by a roughly $1.5-billion gain from the sale of its equity stake in the Samsung Bioepis Joint Venture.
(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)
